Denali Therapeutics stock stood 29.1 percent below its yearly high

Published on 10/08/2026 at 03:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Denali Therapeutics stock posted USD 3.60 million in second-quarter revenue on August 6, 2026, above the USD 2.15 million estimate. Diluted EPS was a USD 0.68 loss, while third-quarter revenue guidance stood at USD 10 million to USD 12 million.

DNLI, US24823R1059, Illustration mit AI erstellt.

Denali Therapeutics (ISIN US24823R1059) stock stood at USD 19.285 on Nasdaq on October 7, 2026, 29.1 percent below its 52-week high of USD 27.30. The valuation is being tested by the commercial launch of AVLAYAH and by the company's second-quarter loss.

Q2 revenue beat the estimate

According to MarketBeat on September 27, 2026, Denali reported USD 3.60 million in revenue for Q2 2026, compared with a USD 2.15 million consensus estimate. That represents a 67.4 percent revenue beat, but diluted EPS came in at a USD 0.68 loss against a projected USD 0.51 loss.

The contrasting figures show the commercial ramp's central tension. Product revenue exceeded the estimate, while the larger-than-expected loss keeps research spending and launch execution central to the stock story.

AVLAYAH guidance sets the next test

At the Cantor healthcare conference on September 9, 2026, management outlined third-quarter revenue guidance of USD 10 million to USD 12 million, according to Investing.com. The midpoint of that range is USD 11 million, more than three times the USD 3.60 million recorded in Q2 2026.

Denali's investor-relations page describes AVLAYAH as approved in the United States and identifies the company as a Nasdaq-listed developer of therapies using its TransportVehicle platform. The commercial product therefore gives investors a measurable revenue checkpoint alongside the longer clinical pipeline.

Analysts see a wide target gap

MarketBeat reported a Moderate Buy consensus from 16 analysts on September 27, 2026, with 13 Buy ratings, two Hold ratings and one Sell rating. The average 12-month target of USD 35.85 lies 85.9 percent above the October 7 price of USD 19.285.

That gap is a market expectation, not a company result. For the stock, the next quantitative checkpoints are revenue conversion from AVLAYAH and the ability to narrow the quarterly loss.

Stock stays below the yearly high

Denali Therapeutics stock was last quoted at USD 19.285 on Nasdaq on October 7, 2026. Its 52-week range was USD 13.28 to USD 27.30, placing the quote 45.1 percent above the yearly low and 29.1 percent below the high.